Keywords: keppra, growth, buy, seen, ucb, belgian, drugs

Keppra growth and a "buy" seen by UCB

Article | 29 March 2004

Print This

Belgian drugs and chemical maker UCB expects sales of its antiepileptic drug Keppra (levetiracetam) to grow 40%-50% in local currency ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in